Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Leads Biolabs (维立志生物) Trading Update

Leads Biolabs (维立志生物) Pre-IPO: Valuation

Leads Biolabs (维立志生物) Pre-IPO: PHIP Updates and Negative Read Through

Leads Biolabs (维立志生物) Pre-IPO: Long Time to Commercialization

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Nanjing Leads Biolabs / Equity Capital Markets

<ul>
<li>Leads Biolabs, a China-based clinical-stage biotechnology company, launched its IPO to raise up to US$144m via a Hong Kong listing.</li>
<li>We look at the deal dynamics and compare the listing with the Duality listing.</li>
<li>The deal values the companies fairly but we see strong sentiment towards quality biotech names.</li>
</ul>


Leads Biolabs, a China-based clinical-stage biotechnology company, launched its IPO to raise up to US$144m via a Hong Kong listing.
We look at the deal dynamics and compare the listing with the Duality listing.
The deal values the companies fairly but we see strong sentiment towards quality biotech names.


Leads Biolabs (维立志生物) IPO: A Duality Repeat?